Flecainide
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Paroxysmal atrial fibrillation / flutter — prevention of recurrence | Adults without structural heart disease and with disabling symptoms | Maintenance (rhythm control) | FDA Approved |
| Paroxysmal supraventricular tachycardia (PSVT) — including AVNRT and AVRT | Adults without structural heart disease and with disabling symptoms | Maintenance prophylaxis | FDA Approved |
| Documented life-threatening sustained ventricular tachycardia | Adults without structural heart disease, when other agents have failed | Maintenance suppression | FDA Approved |
| Pill-in-the-pocket cardioversion of recent-onset AF | Selected adults without structural heart disease, after in-hospital safety check | Single-dose acute conversion | Off-Label |
| Fetal supraventricular tachycardia / fetal atrial flutter | Pregnant patients with hydrops or persistent fetal tachyarrhythmia | Transplacental therapy via maternal dosing | Off-Label |
| Catecholaminergic polymorphic VT (CPVT) | Patients with breakthrough events on beta-blockade | Adjunctive to beta-blocker | Off-Label |
| Pediatric supraventricular and select ventricular tachyarrhythmias | Infants and children supervised by a pediatric electrophysiologist | Specialist-directed therapy | Off-Label (PI dosing provided) |
Flecainide is a potent Class IC antiarrhythmic reserved for symptomatic supraventricular and selected ventricular arrhythmias in patients with structurally normal hearts. The FDA-approved scope is deliberately narrow because the Cardiac Arrhythmia Suppression Trial (CAST) demonstrated excess mortality when Class IC agents were used to suppress asymptomatic ventricular ectopy after myocardial infarction. In contemporary practice, the dominant use is rhythm control of paroxysmal atrial fibrillation, where flecainide remains a guideline-recommended first-line option in patients without coronary artery disease, heart failure, or significant left ventricular hypertrophy. The FDA prescribing information explicitly states that the drug is not recommended for chronic atrial fibrillation.
Pill-in-the-pocket cardioversion (Moderate evidence): A single oral dose of 200 mg (<70 kg) or 300 mg (≥70 kg) converted recent-onset atrial fibrillation to sinus rhythm in approximately 94% of episodes during outpatient self-administration in the Alboni 2004 trial, after an initial in-hospital tolerance check. The strategy requires concurrent AV-nodal blockade and absence of structural heart disease.
Fetal tachyarrhythmias (Moderate evidence): Maternal flecainide is considered a first-line transplacental therapy for fetal SVT or atrial flutter, particularly when complicated by hydrops, in observational series and the AHA scientific statement on fetal cardiac disease.
CPVT breakthrough events (Moderate evidence): Flecainide reduces ventricular ectopy and exercise-induced arrhythmia in CPVT inadequately controlled on beta-blockers; supported by translational ryanodine-receptor data and clinical case series.
Pediatric SVT (Specialist-directed): The FDA prescribing information provides body-surface-area dosing for infants and children, but explicitly notes that safety and efficacy have not been established in randomized placebo-controlled pediatric trials. Use should be supervised by a clinician experienced in pediatric arrhythmia management.
Dosing
All flecainide dosing decisions hinge on the clinical scenario, baseline ECG (especially QRS duration), renal function, and confirmation that structural heart disease has been excluded. Initiation in patients with paroxysmal AF or sustained VT should occur in a monitored setting per AHA/ACC/ACCP/HRS and ESC guidance. Titration intervals must be at least 4 days because of the long elimination half-life and the time required to reach steady state.
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Paroxysmal AF / flutter — rhythm control | 50 mg PO q12h | 100–150 mg PO q12h | 300 mg/day | Increase by 50 mg BID every 4 days; co-prescribe AV-nodal blocker (beta-blocker or non-DHP CCB) to prevent 1:1 conduction during flutter Inpatient initiation often preferred for first dose |
| PSVT — recurrence prevention | 50 mg PO q12h | 100 mg PO q12h | 300 mg/day | Most patients are controlled at 100 mg BID; titrate by 50 mg BID every 4 days based on symptoms and ECG |
| Sustained ventricular tachycardia | 100 mg PO q12h | 150 mg PO q12h | 400 mg/day | Reserved for life-threatening VT in structurally normal hearts; initiate in hospital with telemetry; rapid up-titration in CAST was associated with excess proarrhythmia Most patients do not require more than 300 mg/day |
| Pill-in-the-pocket — recent-onset AF (≥70 kg) | 300 mg PO once | — | 300 mg per episode | Single oral dose taken at symptom onset; AV-nodal blocker administered ≥30 minutes prior; first attempt should be observed in hospital |
| Pill-in-the-pocket — recent-onset AF (<70 kg) | 200 mg PO once | — | 200 mg per episode | Conversion typically within 3–6 hours; if not converted, seek medical care rather than redosing Do not repeat within 24 hours |
| IV loading (outside US, e.g. UK SmPC, ESC) | 2 mg/kg IV over 10 min | 1.5 mg/kg/h × 1 h, then 0.1–0.25 mg/kg/h | 150 mg IV bolus | For acute conversion of AF/SVT in monitored setting; IV formulation is not available in the United States |
Special Population Adjustments
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Renal impairment — CrCl ≤35 mL/min/1.73 m² | 100 mg PO once daily or 50 mg PO q12h | ≤100 mg PO q12h | 200 mg/day typical cap | Titrate at intervals greater than 4 days because steady state is delayed; obtain trough levels Hemodialysis removes ~1% of an oral dose |
| Hepatic impairment — moderate–severe | Generally avoid; if essential, use lowest effective dose with frequent trough monitoring | CYP2D6 metabolism predominates; accumulation likely | ||
| Concomitant amiodarone | Reduce flecainide dose by 50% | 200 mg/day | Recheck trough level and ECG within 7 days of combined therapy | |
| Pediatric — <6 months (BSA dosing) | ~50 mg/m²/day PO ÷ q8–12h | 50–200 mg/m²/day | 200 mg/m²/day | FDA PI specifies BSA dosing for infants; obtain trough levels and avoid dosing with milk feeds (calcium reduces absorption) |
| Pediatric — ≥6 months (BSA dosing) | ~100 mg/m²/day PO ÷ q8–12h | 100–200 mg/m²/day | 200 mg/m²/day | BSA dosing correlates better with plasma levels than weight-based dosing in published pediatric pharmacokinetic studies |
| Fetal SVT or atrial flutter (maternal dosing) | 100 mg PO q8h | 100–150 mg PO q8h | 450 mg/day | Initiated as inpatient with maternal ECG and trough monitoring under maternal–fetal medicine and electrophysiology supervision |
| Older adults / frailty | 50 mg PO q12h | Lowest effective dose | 200 mg/day typical cap | Reduced renal clearance and higher prevalence of subclinical conduction disease; consider trough monitoring |
After every dose increase, repeat the 12-lead ECG once steady state is reached (≥3–5 days). The FDA prescribing information advises caution and dose reduction when the PR interval reaches 0.30 seconds or more, or the QRS duration reaches 0.18 seconds or more. Many electrophysiologists supplement these absolute thresholds with a 25% increase in QRS from baseline as an earlier warning. Flecainide exhibits “use-dependence” — sodium channel blockade worsens at faster heart rates — so a normal resting ECG does not exclude rate-related conduction toxicity, and an exercise ECG is worth obtaining once at maintenance dose.
Pharmacology
Mechanism of Action
Flecainide is a potent blocker of the cardiac fast inward sodium current (INa), binding preferentially to channels in the open and inactivated states. This produces marked slowing of phase 0 depolarisation with relatively little effect on action potential duration — the hallmark of the Vaughan Williams Class IC profile. Conduction velocity is slowed throughout the atrium, AV node, His–Purkinje system, and ventricle, manifesting clinically as PR and QRS prolongation. Flecainide also blocks the cardiac ryanodine receptor (RyR2) and inhibits the rapid delayed-rectifier potassium current (IKr), although these secondary effects are clinically modest at therapeutic concentrations.
The RyR2 effect is the basis for flecainide’s emerging role in catecholaminergic polymorphic VT, where leaky calcium release underlies arrhythmogenesis. Sodium channel blockade is “use-dependent,” intensifying at faster heart rates — useful for terminating tachyarrhythmias but a key driver of proarrhythmia and 1:1 atrial flutter conduction when AV-nodal blockade is inadequate.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~90%; Tmax 2–3 h; food and antacids do not meaningfully alter absorption (milk-based feeds reduce absorption in young infants) | Predictable systemic exposure; steady BID dosing is required because of pharmacodynamic profile |
| Distribution | Vd ~10 L/kg; protein binding ~40%; crosses placenta and is excreted in breast milk | Extensive tissue distribution; transplacental transfer is the rationale for treating fetal SVT via maternal dosing |
| Metabolism | ~70% hepatic via CYP2D6 to two main metabolites (one with reduced activity); ~30% excreted unchanged in urine | CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine, bupropion) raise plasma levels; CYP2D6 poor metabolisers reach higher concentrations on standard doses |
| Elimination | Terminal t½ ~20 h (range 12–27 h); steady state in 3–5 days; renal excretion of parent drug rises with urinary acidification and falls with alkalinisation | Steady-state achieved in ~5 days, so titration intervals shorter than 4 days risk over-rapid escalation; renal failure substantially prolongs half-life |
Side Effects
Incidence figures below are drawn from the FDA prescribing information and the well-controlled multicenter ventricular and supraventricular arrhythmia trials reported by Conard, Anderson, and the Flecainide Supraventricular Tachycardia Study Group. The cardiovascular toxicity profile — proarrhythmia, conduction disease, and negative inotropy — is the dominant safety concern; non-cardiac effects are mostly neurologic and visual and are typically dose-related.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Dizziness / lightheadedness | ~30% | Includes unsteadiness and near-syncope; often dose-related and overlapping with visual symptoms |
| Visual disturbance (blurred vision, decreased acuity, scotomata) | ~28% | Dose-related; suggests trough check before further up-titration |
| Headache | ~10% | Usually mild and transient; persistent severe headache should prompt drug-level review |
| Dyspnea | ~10% | Distinguish neutral cardiac symptom from emerging heart failure — examine and obtain BNP if uncertain |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | ~9% | Take with food if troublesome; rarely dose-limiting |
| Palpitations (non-arrhythmic) | ~6% | Confirm rhythm with ambulatory ECG before assuming benign cause |
| Asthenia | ~6% | May overlap with reduced cardiac output — assess LV function if persistent |
| Fatigue | ~6% | Dose-related; consider trough check before dose escalation |
| Chest pain (non-ischaemic) | ~5% | Always exclude ischaemia first; structural heart disease is a contraindication |
| Tremor | ~4% | Fine resting tremor; often resolves on dose reduction |
| Constipation / abdominal pain | ~3% | Manage with usual measures; rarely requires drug change |
| Edema | ~3% | Concerning if accompanied by dyspnea or weight gain — evaluate for HF exacerbation |
| Hypoesthesia / paresthesia | ~1–3% | Dose-related; a marker of central nervous system exposure |
| Anxiety / nervousness | ~2% | Typically mild; may overlap with palpitations awareness |
| New first-degree AV block (PR ≥0.20 sec) | ~30% develop new first-degree AV block per FDA PI | Expected pharmacologic effect; alarming only if PR reaches ≥0.30 sec or higher-degree block emerges |
| New bundle branch block | ~4% | FDA PI: 4% of patients develop new BBB on flecainide; warrants dose reduction or discontinuation |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Proarrhythmia — incessant or new sustained VT | ~1% PSVT; ~7% paroxysmal AF; ~13% sustained VT (initiated at 200 mg/day per FDA PI) | ~80% within first 2 weeks | Permanent discontinuation; IV sodium bicarbonate is the antidote of choice for severe sodium-channel toxicity |
| 1:1 atrial flutter conduction with hemodynamic compromise | Reported in patients without concurrent AV-nodal blockade | During flutter episode | Emergency cardioversion; ensure AV-nodal blocker (beta-blocker or non-DHP CCB) is on board before any future episode |
| New or worsened heart failure | ~6% in sustained VT trials (patients often had pre-existing CHF) | Days to months | Discontinue flecainide; manage HF; do not rechallenge |
| Increased mortality (post-MI / structural heart disease) — CAST | RR 2.5 for total mortality (encainide+flecainide vs placebo) | Months | Avoid in any structural heart disease — this is a contraindication |
| Severe conduction block — high-grade AV block, sinus arrest | Uncommon; risk increases with PR ≥0.30 sec or QRS ≥0.18 sec | Days to weeks | Stop drug; temporary pacing if symptomatic; isoproterenol and bicarbonate for refractory toxicity |
| Brugada-pattern unmasking | Rare (used as a diagnostic provocation test in suspected cases) | Hours of dosing | Discontinue; refer to electrophysiology for risk stratification |
| Hepatotoxicity — cholestatic or hepatocellular injury | Rare | Weeks to months | Stop drug if ALT >3× ULN with symptoms or >5× ULN otherwise; monitor recovery |
| Neutropenia / agranulocytosis | Very rare | Weeks | Discontinue; obtain CBC if febrile or signs of infection |
| Pulmonary toxicity — interstitial lung disease | Very rare | Months | High-resolution CT chest; permanent discontinuation if confirmed |
| Increase in pacing threshold | Reported — pacing threshold may double or more | Days | Reassess pacing threshold and reprogram pacemaker after initiation in pacemaker-dependent patients |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Cardiac adverse events (proarrhythmia, HF, conduction) | ~7–11% | Higher in PAF (Anderson 1989: 11%) and sustained VT trials than in PSVT |
| Visual / neurologic intolerance | ~3–5% | Often dose-related — trial of dose reduction before discontinuation |
| Conduction abnormality on ECG | ~2–4% | PR ≥0.30 sec, QRS ≥0.18 sec, or new bundle branch block prompts dose reduction or withdrawal |
| Hepatic enzyme elevation | <1% | Generally reversible on discontinuation |
The most consequential adverse effect is incessant or sustained ventricular arrhythmia. A clinically useful workflow is to obtain a baseline 12-lead ECG, repeat it 3–5 days after every dose change, and consider an exercise ECG before reaching maintenance dose. Treat severe sodium-channel toxicity with IV sodium bicarbonate (1–2 mEq/kg bolus then infusion), correct hypokalaemia and hypomagnesaemia, and use lipid emulsion or extracorporeal support for refractory cases. Class IA, IC, and III antiarrhythmics should not be given as rescue agents because they worsen toxicity.
Drug Interactions
Flecainide is metabolised primarily by CYP2D6, so interactions cluster around CYP2D6 inhibitors (which raise concentrations) and inducers (which lower them). The second axis of interaction is pharmacodynamic — additive negative inotropy, AV-nodal slowing, or sodium-channel blockade with drugs of similar action. Renal handling is also pH-dependent: alkalinising agents reduce flecainide clearance.
Monitoring
Monitoring is built around three priorities: (1) confirming that structural heart disease is absent at baseline, (2) detecting conduction toxicity and proarrhythmia early, and (3) keeping plasma exposure within the narrow therapeutic range, especially after dose changes or when interacting drugs are added.
-
Echocardiogram
Before initiation
Routine Document LVEF, wall motion, and significant LV hypertrophy. Flecainide is contraindicated when LVEF is reduced or when there is clinically meaningful structural heart disease, so this assessment is mandatory for safe prescribing. -
Stress test or coronary imaging
Before initiation in adults >40 y or with CAD risk factors
Routine Exclude obstructive coronary disease before starting maintenance flecainide, given the CAST signal of excess mortality in patients with ischaemic heart disease. -
12-lead ECG
Baseline; 3–5 days after each dose change; then every 3–6 months
Routine Track QRS duration (consider dose reduction if QRS reaches ≥0.18 sec or widens by >25% from baseline), PR interval (caution at ≥0.30 sec), and look for new bundle branch block. Record heart rate at rest and on standing. -
Exercise ECG
Once at maintenance dose; repeat after major dose change
Trigger-based Use-dependence means QRS may widen disproportionately at higher heart rates. An exercise study unmasks rate-related conduction toxicity that a resting ECG can miss. -
Plasma trough level
Once at steady state; whenever an interacting drug is added; with renal/hepatic change
Trigger-based Drawn less than 1 hour pre-dose at steady state (after at least 5 doses on a stable regimen). Target 0.2–1.0 mcg/mL. Levels above ~1.0 mcg/mL are associated with a higher rate of cardiac adverse events. -
Renal function
Baseline, then annually or with clinical change
Routine Reduced CrCl prolongs half-life and raises plasma levels. The threshold for adjustment per the FDA PI is CrCl ≤35 mL/min/1.73 m². Reassess sooner if a new nephrotoxin or dehydration episode occurs. -
Hepatic function
Baseline; then if symptoms of hepatotoxicity
Trigger-based Routine surveillance is not required, but check ALT, AST, and bilirubin for unexplained fatigue, jaundice, or abdominal pain. -
Serum potassium and magnesium
Baseline, then per clinical setting
Routine Hypokalaemia and hypomagnesaemia exacerbate proarrhythmia. Replete aggressively in patients on diuretics or with GI losses. -
Symptom and rhythm review
3 months, then every 6–12 months
Routine Ambulatory ECG (24–72 h Holter or patch monitor) at maintenance dose to confirm rhythm-control efficacy and exclude silent atrial flutter with rapid AV conduction.
Contraindications & Cautions
The Cardiac Arrhythmia Suppression Trial (CAST) showed an increased rate of death or non-fatal cardiac arrest among patients with recent myocardial infarction and asymptomatic ventricular ectopy who received flecainide or encainide compared with placebo. Total mortality was 7.7% on encainide or flecainide versus 3.0% on placebo (relative risk ~2.5).
Class IC antiarrhythmics including flecainide should not be used in patients with structural heart disease — including recent MI, reduced left ventricular ejection fraction, clinically significant LV hypertrophy, obstructive coronary artery disease, or chronic atrial fibrillation. Use in atrial fibrillation or flutter is restricted to symptomatic paroxysmal disease in structurally normal hearts, when the risk-benefit profile favours rhythm control.
Absolute Contraindications
- Structural heart disease — recent or remote MI, reduced LVEF, clinically significant LVH, obstructive coronary artery disease, prior cardiac arrest from non-flecainide-related VT/VF.
- Pre-existing second- or third-degree AV block without a permanent pacemaker.
- Bifascicular or trifascicular bundle branch block, or right bundle branch block with a left hemiblock, without a pacemaker.
- Cardiogenic shock or any state of haemodynamic instability.
- Sick sinus syndrome / sinus node dysfunction without a pacemaker, including symptomatic bradycardia.
- Chronic (persistent or permanent) atrial fibrillation — explicitly noted as not recommended in the FDA prescribing information.
- Known hypersensitivity to flecainide or any formulation excipient.
Relative Contraindications (Specialist Input Recommended)
- Pre-existing PR ≥0.30 sec or QRS ≥0.18 sec — narrow margin before clinically meaningful conduction toxicity per the FDA PI.
- Concomitant strong CYP2D6 inhibitor (e.g. ritonavir, dronedarone) — interaction databases consider these combinations contraindicated; use only with electrophysiology and pharmacology input if unavoidable.
- Severe renal impairment (CrCl <20 mL/min) — drug accumulation; manage with electrophysiology and clinical pharmacology input.
- Moderate-to-severe hepatic impairment — dependence on CYP2D6 metabolism makes accumulation unpredictable.
- Pregnancy — used only when benefits clearly outweigh risks (most often fetal arrhythmia or otherwise refractory maternal SVT) under maternal–fetal medicine and electrophysiology supervision.
- Permanent pacemaker dependence — flecainide can substantially raise pacing thresholds, requiring threshold reassessment after initiation.
- Known or suspected Brugada syndrome outside of supervised diagnostic provocation testing.
Use with Caution
- Mild renal or hepatic impairment — start at the lower end of the dosing range and titrate slowly.
- Older adults / frailty — reduced renal clearance and higher prevalence of subclinical conduction disease.
- Hypokalaemia or hypomagnesaemia — correct before initiation and during therapy.
- Concomitant negative inotropes at higher doses (verapamil, diltiazem, high-dose beta-blockers) — monitor LV function and conduction.
- Patients receiving urinary alkalinisers or following alkaline diets — counsel about consistent hydration and consider trough levels.
- Pediatric patients — body-surface-area dosing in infants and children; avoid co-administration with milk feeds; therapy supervised by a pediatric electrophysiologist.
Patient Counselling
Purpose of Therapy
Explain that flecainide is being prescribed to keep the heart in a normal rhythm — it does not cure the underlying tendency to atrial fibrillation or supraventricular tachycardia, but most people on it will have far fewer and shorter episodes. The goal is symptom reduction and quality of life, not disease cure. For patients using a pill-in-the-pocket strategy, emphasise that the single dose is for sudden episodes confirmed earlier with their cardiologist — not for daily use.
How to Take
Maintenance flecainide is taken twice a day at roughly 12-hour intervals, with or without food. Doses should not be doubled if missed; instead, take the next scheduled dose at the usual time. Do not stop suddenly without speaking to the prescribing clinician, since arrhythmia may rebound. Patients should keep a list of all medicines, herbal products, and over-the-counter remedies (especially antacids containing sodium bicarbonate) and check with the pharmacist before adding anything new. A medical alert card or bracelet listing the diagnosis and flecainide therapy is reasonable for patients with a history of dangerous arrhythmias.
Sources
- U.S. Food and Drug Administration. Flecainide acetate tablets — prescribing information (DailyMed). dailymed.nlm.nih.gov Primary FDA labelling: indications, dosing, boxed warning, adverse-event tables, and pediatric BSA dosing.
- Electronic Medicines Compendium. Flecainide acetate Summary of Product Characteristics (UK SmPC). medicines.org.uk/emc European labelling reference, including IV preparation guidance not available in the United States.
- Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781–788. doi.org/10.1056/NEJM199103213241201 CAST trial — defined the boxed-warning population. Excess mortality with flecainide and encainide post-MI (RR ~2.5 for total mortality).
- Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the “pill-in-the-pocket” approach. N Engl J Med. 2004;351(23):2384–2391. doi.org/10.1056/NEJMoa041233 Pivotal trial validating self-administered single-dose flecainide (200 mg if <70 kg, 300 mg if ≥70 kg) for AF cardioversion in selected outpatients.
- Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation. 1989;80(6):1557–1570. doi.org/10.1161/01.CIR.80.6.1557 Foundational randomised data on flecainide for paroxysmal AF supporting the FDA indication; ~11% cardiac AE rate documented.
- Henthorn RW, Waldo AL, Anderson JL, et al. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation. 1991;83(1):119–125. doi.org/10.1161/01.CIR.83.1.119 Placebo-controlled crossover trial demonstrating flecainide efficacy in PSVT — 79% freedom from PSVT vs 15% on placebo.
- Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149(1):e1–e156. doi.org/10.1161/CIR.0000000000001193 Most recent US guideline placing flecainide as a first-line rhythm-control option in patients without structural heart disease.
- Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the EACTS. Eur Heart J. 2024;45(36):3314–3414. doi.org/10.1093/eurheartj/ehae176 European guideline parallel to the ACC/AHA document, including pill-in-the-pocket criteria and contraindication framing.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi.org/10.1093/eurheartj/ehac262 Defines flecainide’s restricted role in ventricular arrhythmias and its use in CPVT.
- Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15(4):380–383. doi.org/10.1038/nm.1942 Translational study identifying RyR2 inhibition as the mechanism underlying flecainide’s role in CPVT.
- Conard GJ, Ober RE. Metabolism of flecainide. Am J Cardiol. 1984;53(5):41B–51B. doi.org/10.1016/0002-9149(84)90501-0 Classic pharmacokinetic study quantifying CYP2D6-mediated metabolism, ~30% renal excretion of unchanged drug, and the 12–27 hour half-life range.
- Conard GJ, Carlson GL, Frost JW, Ober RE. Human plasma pharmacokinetics of flecainide acetate (R-818), a new antidysrhythmic, following single oral and intravenous doses in healthy subjects. Clin Pharmacol Ther. 1979;25:228 (PMID 759259 series). Original human pharmacokinetic data on flecainide bioavailability (~90%) and distribution.
- Perry JC, McQuinn RL, Smith RT Jr, Gothing C, Fredell P, Garson A Jr. Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. J Am Coll Cardiol. 1989;14(1):185–191. doi.org/10.1016/0735-1097(89)90070-3 Demonstrates that body-surface-area dosing correlates better with plasma flecainide levels than weight-based dosing in pediatric patients.
- Perry JC, Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J. 1992;124(6):1614–1621. doi.org/10.1016/0002-8703(92)90081-6 Comprehensive pediatric safety and dosing review — effective dose range 100–200 mg/m²/day; importance of milk-feeding interaction.
- Aliot E, De Roy L, Capucci A, et al. Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angeiol (Paris). 2003;52(1):34–40. European outpatient safety dataset supporting modern outpatient maintenance dosing.